Halozyme Therapeutics Inc (HALO)vsRegeneron Pharmaceuticals Inc (REGN)
HALO
Halozyme Therapeutics Inc
$71.53
-0.10%
HEALTHCARE · Cap: $8.24B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.46%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 889% more annual revenue ($14.92B vs $1.51B). REGN leads profitability with a 29.6% profit margin vs 23.1%. REGN trades at a lower P/E of 14.7x. HALO earns a higher WallStSmart Score of 70/100 (B).
HALO
Strong Buy70
out of 100
Grade: B
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HALO.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 159 in profit
Strong operational efficiency at 49.0%
Revenue surging 42.2% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 31.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Weak financial health signals
Trading at 38.7x book value
Elevated debt levels
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 49.0%. Revenue growth of 42.2% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : HALO
The primary concerns for HALO are Altman Z-Score, Piotroski F-Score, Price/Book. Debt-to-equity of 9.76 is elevated, increasing financial risk.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
HALO carries more volatility with a beta of 0.87 — expect wider price swings.
HALO is growing revenue faster at 42.2% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HALO scores higher overall (70/100 vs 64/100), backed by strong 23.1% margins and 42.2% revenue growth. REGN offers better value entry with a 53.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?